Shedding new light on female fertility: The role of vitamin D

Reviews in Endocrine and Metabolic Disorders

Volumn 18, Issue 3, 2017, Pages 273-283

  Muscogiuri, Giovanna ^a   Altieri, Barbara ^b   de Angelis, Cristina ^a   Palomba, Stefano ^c   Pivonello, Rosario ^a   Colao, Annamaria ^a   Orio, Francesco ^d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

^d UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

Author keywords

Endometriosis; Female fertility; PCOS; Vitamin D

Indexed keywords

BIOLOGICAL MARKER; OXYGENASE; SEX HORMONE; VITAMIN D; VITAMIN D RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; ENDOMETRIOSIS; FEMALE FERTILITY; FEMALE INFERTILITY; HUMAN; HYPERANDROGENISM; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; OVARIAN RESERVE; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; REGULATORY MECHANISM; REVIEW; STEROIDOGENESIS; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; BLOOD; COMPLICATION; DIET THERAPY; DIETARY SUPPLEMENT; DRUG EFFECTS; FEMALE; FERTILITY; PHYSIOLOGY; PREGNANCY; SUNLIGHT;

DIETARY SUPPLEMENTS; ENDOMETRIOSIS; FEMALE; FERTILITY; HUMANS; INFERTILITY, FEMALE; POLYCYSTIC OVARY SYNDROME; PREGNANCY; SUNLIGHT; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 85009902135     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-017-9407-2     Document Type: Review

References (116)

1. Bhan I. Vitamin d binding protein and bone health. Int J Endocrinol. 2014;2014:561214. doi:10.1155/2014/561214.
2. Muscogiuri G, Altieri B, Annweiler C, Balercia G, Pal HB, Boucher BJ, et al. Vitamin D and chronic diseases: the current state of the art. Arch Toxicol. 2016; doi:10.1007/s00204-016-1804-x.
3. Muscogiuri G, Mitri J, Mathieu C, Badenhoop K, Tamer G, Orio F, et al. Mechanisms in endocrinology: vitamin D as a potential contributor in endocrine health and disease. Eur J Endocrinol / European Federation of Endocrine Societies. 2014;171(3):R101–10. doi:10.1530/EJE-14-0158.
4. D'Aurizio F, Villalta D, Metus P, Doretto P, Tozzoli R. Is vitamin D a player or not in the pathophysiology of autoimmune thyroid diseases? Autoimmun Rev. 2015;14(5):363–9. doi:10.1016/j.autrev.2014.10.008.
5. Muscogiuri G, Altieri B, Penna-Martinez M, Badenhoop K. Focus on vitamin D and the adrenal gland. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2015;47(4):239–46. doi:10.1055/s-0034-1396893.
6. Moukayed M, Grant WB. Molecular link between vitamin D and cancer prevention. Nutrients. 2013;5(10):3993–4021. doi:10.3390/nu5103993.
7. Altieri B, Grant WB, Casa SD, Orio F, Pontecorvi A, Colao A, et al. Vitamin D and pancreas: the role of sunshine vitamin in the pathogenesis of diabetes mellitus and pancreatic cancer. Crit Rev Food Sci Nutr. 2016; doi:10.1080/10408398.2015.1136922.
8. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009;94(1):26–34. doi:10.1210/jc.2008-1454.
9. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol. 2005;97(1–2):93–101. doi:10.1016/j.jsbmb.2005.06.002.
10. Lerchbaum E, Obermayer-Pietsch B. Vitamin D and fertility: a systematic review. Eur J Endocrinol / European Federation of Endocrine Societies. 2012;166(5):765–78. doi:10.1530/EJE-11-0984.
11. Anagnostis P, Karras S, Goulis DG. Vitamin D in human reproduction: a narrative review. Int J Clin Pract. 2013;67(3):225–35. doi:10.1111/ijcp.12031.
12. Kinuta K, Tanaka H, Moriwake T, Aya K, Kato S, Seino Y. Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinology. 2000;141(4):1317–24. doi:10.1210/endo.141.4.7403.
13. Halhali A, Acker GM, Garabedian M. 1,25-dihydroxyvitamin D3 induces in vivo the decidualization of rat endometrial cells. J Reprod Fertil. 1991;91(1):59–64.
14. Rojansky N, Brzezinski A, Schenker JG. Seasonality in human reproduction: an update. Hum Reprod. 1992;7(6):735–45.
15. Thill M, Becker S, Fischer D, Cordes T, Hornemann A, Diedrich K, et al. Expression of prostaglandin metabolising enzymes COX-2 and 15-PGDH and VDR in human granulosa cells. Anticancer Res. 2009;29(9):3611–8.
16. Parikh G, Varadinova M, Suwandhi P, Araki T, Rosenwaks Z, Poretsky L et al. Vitamin D regulates steroidogenesis and insulin-like growth factor binding protein-1 (IGFBP-1) production in human ovarian cells. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2010;42(10):754–7. doi:10.1055/s-0030-1262837.
17. Weisman Y, Harell A, Edelstein S, David M, Spirer Z, Golander A. 1 alpha, 25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 in vitro synthesis by human decidua and placenta. Nature. 1979;281(5729):317–9.
18. Tanamura A, Nomura S, Kurauchi O, Furui T, Mizutani S, Tomoda Y. Purification and characterization of 1,25(OH)2D3 receptor from human placenta. J Obstet Gynaecol (Tokyo 1995). 1995;21(6):631–9.
19. Agic A, Xu H, Altgassen C, Noack F, Wolfler MM, Diedrich K, et al. Relative expression of 1,25-dihydroxyvitamin D3 receptor, vitamin D 1 alpha-hydroxylase, vitamin D 24-hydroxylase, and vitamin D 25-hydroxylase in endometriosis and gynecologic cancers. Reprod Sci. 2007;14(5):486–97. doi:10.1177/1933719107304565.
20. Perez-Fernandez R, Alonso M, Segura C, Munoz I, Garcia-Caballero T, Diguez C. Vitamin D receptor gene expression in human pituitary gland. Life Sci. 1997;60(1):35–42.
21. Barrera D, Avila E, Hernandez G, Mendez I, Gonzalez L, Halhali A, et al. Calcitriol affects hCG gene transcription in cultured human syncytiotrophoblasts. Reprod Biol Endocrinol. 2008;6:3. doi:10.1186/1477-7827-6-3.
22. Henry HL, Norman AW. Vitamin D: metabolism and biological actions. Annu Rev Nutr. 1984;4:493–520. doi:10.1146/annurev.nu.04.070184.002425.
23. Vigano P, Lattuada D, Mangioni S, Ermellino L, Vignali M, Caporizzo E, et al. Cycling and early pregnant endometrium as a site of regulated expression of the vitamin D system. J Mol Endocrinol. 2006;36(3):415–24. doi:10.1677/jme.1.01946.
24. Fischer D, Thome M, Becker S, Cordes T, Diedrich K, Friedrich M, et al. 25-hydroxyvitamin D3 1alpha-hydroxylase splice variants in benign and malignant ovarian cell lines and tissue. Anticancer Res. 2009;29(9):3627–33.
25. Stephanou A, Ross R, Handwerger S. Regulation of human placental lactogen expression by 1,25-dihydroxyvitamin D3. Endocrinology. 1994;135(6):2651–6. doi:10.1210/endo.135.6.7988455.
26. Tuan RS, Moore CJ, Brittingham JW, Kirwin JJ, Akins RE, Wong M. In vitro study of placental trophoblast calcium uptake using JEG-3 human choriocarcinoma cells. J Cell Sci. 1991;98(Pt 3):333–42.
27. Belkacemi L, Gariepy G, Mounier C, Simoneau L, Lafond J. Expression of calbindin-D28k (CaBP28k) in trophoblasts from human term placenta. Biol Reprod. 2003;68(6):1943–50. doi:10.1095/biolreprod.102.009373.
28. Du H, Daftary GS, Lalwani SI, Taylor HS. Direct regulation of HOXA10 by 1,25-(OH)2D3 in human myelomonocytic cells and human endometrial stromal cells. Mol Endocrinol. 2005;19(9):2222–33. doi:10.1210/me.2004-0336.
29. Merhi Z, Doswell A, Krebs K, Cipolla M. Vitamin D alters genes involved in follicular development and steroidogenesis in human cumulus granulosa cells. J Clin Endocrinol Metab. 2014;99(6):E1137–45. doi:10.1210/jc.2013-4161.
30. Barrera D, Avila E, Hernandez G, Halhali A, Biruete B, Larrea F, et al. Estradiol and progesterone synthesis in human placenta is stimulated by calcitriol. J Steroid Biochem Mol Biol. 2007;103(3–5):529–32. doi:10.1016/j.jsbmb.2006.12.097.
31. Sun T, Zhao Y, Mangelsdorf DJ, Simpson ER. Characterization of a region upstream of exon I.1 of the human CYP19 (aromatase) gene that mediates regulation by retinoids in human choriocarcinoma cells. Endocrinology. 1998;139(4):1684–91. doi:10.1210/endo.139.4.5959.
32. Krishnan AV, Swami S, Peng L, Wang J, Moreno J, Feldman D. Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology. 2010;151(1):32–42. doi:10.1210/en.2009-0855.
33. Malloy PJ, Peng L, Wang J, Feldman D. Interaction of the vitamin D receptor with a vitamin D response element in the Mullerian-inhibiting substance (MIS) promoter: regulation of MIS expression by calcitriol in prostate cancer cells. Endocrinology. 2009;150(4):1580–7. doi:10.1210/en.2008-1555.
34. Merhi ZO, Seifer DB, Weedon J, Adeyemi O, Holman S, Anastos K, et al. Circulating vitamin D correlates with serum antimullerian hormone levels in late-reproductive-aged women: Women's interagency HIV study. Fertil Steril. 2012;98(1):228–34. doi:10.1016/j.fertnstert.2012.03.029.
35. Jamil Z, Fatima SS, Ahmed K, Malik R. Anti-Mullerian hormone: above and beyond conventional ovarian reserve markers. Dis Markers. 2016;2016:5246217. doi:10.1155/2016/5246217.
36. Knight PG, Glister C. TGF-beta superfamily members and ovarian follicle development. Reproduction. 2006;132(2):191–206. doi:10.1530/rep.1.01074.
37. Parry JP, Moran T, Koch CA. Ovarian reserve testing. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2016.
38. Krishnan AV, Moreno J, Nonn L, Malloy P, Swami S, Peng L, et al. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem Mol Biol. 2007;103(3–5):694–702. doi:10.1016/j.jsbmb.2006.12.051.
39. Dennis NA, Houghton LA, Jones GT, van Rij AM, Morgan K, McLennan IS. The level of serum anti-Mullerian hormone correlates with vitamin D status in men and women but not in boys. J Clin Endocrinol Metab. 2012;97(7):2450–5. doi:10.1210/jc.2012-1213.
40. Jukic AM, Steiner AZ, Baird DD. Association between serum 25-hydroxyvitamin D and ovarian reserve in premenopausal women. Menopause. 2015;22(3):312–6. doi:10.1097/GME.0000000000000312.
41. Kwiecinksi GG, Petrie GI, DeLuca HF. 1,25-dihydroxyvitamin D3 restores fertility of vitamin D-deficient female rats. Am J Phys. 1989;256(4 Pt 1):E483–7.
42. Halloran BP, DeLuca HF. Effect of vitamin D deficiency on fertility and reproductive capacity in the female rat. J Nutr. 1980;110(8):1573–80.
43. Yoshizawa T, Handa Y, Uematsu Y, Takeda S, Sekine K, Yoshihara Y, et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet. 1997;16(4):391–6. doi:10.1038/ng0897-391.
44. Sun W, Xie H, Ji J, Zhou X, Goltzman D, Miao D. Defective female reproductive function in 1,25(OH)2D-deficient mice results from indirect effect mediated by extracellular calcium and/or phosphorus. Am J Physiol Endocrinol Metab. 2010;299(6):E928–35. doi:10.1152/ajpendo.00378.2010.
45. Panda DK, Miao D, Tremblay ML, Sirois J, Farookhi R, Hendy GN, et al. Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci U S A. 2001;98(13):7498–503. doi:10.1073/pnas.131029498.
46. Johnson LE, DeLuca HF. Vitamin D receptor null mutant mice fed high levels of calcium are fertile. J Nutr. 2001;131(6):1787–91.
47. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008;29(6):726–76. doi:10.1210/er.2008-0004.
48. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745–9. doi:10.1210/jc.2003-032046.
49. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544–51. doi:10.1093/humrep/dep399.
50. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and Pcos Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome--Part 1. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2015;21(11):1291–300. doi:10.4158/EP15748.DSC.
51. Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996;81(3):942–7. doi:10.1210/jcem.81.3.8772555.
52. Talbott EO, Zborowskii JV, Boudraux MY. Do women with polycystic ovary syndrome have an increased risk of cardiovascular disease? Review of the evidence Minerva Ginecol. 2004;56(1):27–39.
53. Thomson RL, Spedding S, Buckley JD. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol. 2012;77(3):343–50. doi:10.1111/j.1365-2265.2012.04434.x.
54. He C, Lin Z, Robb SW, Ezeamama AE. Serum vitamin D levels and polycystic ovary syndrome: a systematic review and meta-analysis. Nutrients. 2015;7(6):4555–77. doi:10.3390/nu7064555.
55. Johnson JA, Grande JP, Roche PC, Kumar R. Immunohistochemical detection and distribution of the 1,25-dihydroxyvitamin D3 receptor in rat reproductive tissues. Histochem Cell Biol. 1996;105(1):7–15.
56. Wojtusik J, Johnson PA. Vitamin D regulates anti-Mullerian hormone expression in granulosa cells of the hen. Biol Reprod. 2012;86(3):91. doi:10.1095/biolreprod.111.094110.
57. Chang HM, Klausen C, Leung PC. Antimullerian hormone inhibits follicle-stimulating hormone-induced adenylyl cyclase activation, aromatase expression, and estradiol production in human granulosa-lutein cells. Fertil Steril. 2013;100(2):585–92. e1 doi:10.1016/j.fertnstert.2013.04.019.
58. Lee CT, Wang JY, Chou KY, Hsu MI. 1,25-dihydroxyvitamin D3 increases testosterone-induced 17beta-estradiol secretion and reverses testosterone-reduced connexin 43 in rat granulosa cells. Reprod Biol Endocrinol: RB&E. 2014;12:90. doi:10.1186/1477-7827-12-90.
59. Van Belle TL, Gysemans C, Mathieu C. Vitamin D and diabetes: the odd couple. Trends Endocrinol Metab: TEM. 2013;24(11):561–8. doi:10.1016/j.tem.2013.07.002.
60. Sung CC, Liao MT, Lu KC, Wu CC. Role of vitamin D in insulin resistance. J Biomed Biotechnol. 2012;2012:634195. doi:10.1155/2012/634195.
61. Shahrokhi SZ, Ghaffari F, Kazerouni F. Role of vitamin D in female reproduction. Clinica chimica acta; Int J Clin Chem. 2016;455:33–8. doi:10.1016/j.cca.2015.12.040.
62. Colonese F, Lagana AS, Colonese E, Sofo V, Salmeri FM, Granese R, et al. The pleiotropic effects of vitamin D in gynaecological and obstetric diseases: an overview on a hot topic. Biomed Res Int. 2015;2015:986281. doi:10.1155/2015/986281.
63. Maestro B, Campion J, Davila N, Calle C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J. 2000;47(4):383–91.
64. Leal MA, Aller P, Mas A, Calle C. The effect of 1,25-dihydroxyvitamin D3 on insulin binding, insulin receptor mRNA levels, and isotype RNA pattern in U-937 human promonocytic cells. Exp Cell Res. 1995;217(2):189–94. doi:10.1006/excr.1995.1078.
65. Maestro B, Molero S, Bajo S, Davila N, Calle C. Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D(3). Cell Biochem Funct. 2002;20(3):227–32. doi:10.1002/cbf.951.
66. Maestro B, Davila N, Carranza MC, Calle C. Identification of a vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol. 2003;84(2–3):223–30.
67. Dunlop TW, Vaisanen S, Frank C, Molnar F, Sinkkonen L, Carlberg C. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor. J Mol Biol. 2005;349(2):248–60. doi:10.1016/j.jmb.2005.03.060.
68. Ojuka EO. Role of calcium and AMP kinase in the regulation of mitochondrial biogenesis and GLUT4 levels in muscle. Proc Nutr Soc. 2004;63(2):275–8. doi:10.1079/PNS2004339.
69. Draznin B, Sussman K, Kao M, Lewis D, Sherman N. The existence of an optimal range of cytosolic free calcium for insulin-stimulated glucose transport in rat adipocytes. J Biol Chem. 1987;262(30):14385–8.
70. Draznin B, Lewis D, Houlder N, Sherman N, Adamo M, Garvey WT, et al. Mechanism of insulin resistance induced by sustained levels of cytosolic free calcium in rat adipocytes. Endocrinology. 1989;125(5):2341–9. doi:10.1210/endo-125-5-2341.
71. Reusch JE, Begum N, Sussman KE, Draznin B. Regulation of GLUT-4 phosphorylation by intracellular calcium in adipocytes. Endocrinology. 1991;129(6):3269–73. doi:10.1210/endo-129-6-3269.
72. Calle C, Maestro B, Garcia-Arencibia M. Genomic actions of 1,25-dihydroxyvitamin D3 on insulin receptor gene expression, insulin receptor number and insulin activity in the kidney, liver and adipose tissue of streptozotocin-induced diabetic rats. BMC Mol Biol. 2008;9:65. doi:10.1186/1471-2199-9-65.
73. Wehr E, Trummer O, Giuliani A, Gruber HJ, Pieber TR, Obermayer-Pietsch B. Vitamin D-associated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome. Eur J Endocrinol / European Federation of Endocrine Societies. 2011;164(5):741–9. doi:10.1530/EJE-11-0134.
74. Zadeh-Vakili A, Ramezani Tehrani F, Daneshpour MS, Zarkesh M, Saadat N, Azizi F. Genetic polymorphism of vitamin D receptor gene affects the phenotype of PCOS. Gene. 2013;515(1):193–6. doi:10.1016/j.gene.2012.11.049.
75. Jedrzejuk D, Laczmanski L, Milewicz A, Kuliczkowska-Plaksej J, Lenarcik-Kabza A, Hirnle L, et al. Classic PCOS phenotype is not associated with deficiency of endogenous vitamin D and VDR gene polymorphisms rs731236 (TaqI), rs7975232 (ApaI), rs1544410 (BsmI), rs10735810 (FokI): a case-control study of lower Silesian women. Gynecol Endocrinol. 2015;31(12):976–9. doi:10.3109/09513590.2015.1062865.
76. Mahmoudi T, Majidzadeh AK, Farahani H, Mirakhorli M, Dabiri R, Nobakht H, et al. Association of vitamin D receptor gene variants with polycystic ovary syndrome: a case control study. Int J Reprod Biomed (Yazd). 2015;13(12):793–800.
77. Lin MW, Tsai SJ, Chou PY, Huang MF, Sun HS, Wu MH. Vitamin D receptor 1a promotor −1521 G/C and −1012 a/G polymorphisms in polycystic ovary syndrome. Taiwan J Obstet Gynecol. 2012;51(4):565–71. doi:10.1016/j.tjog.2012.09.011.
78. Li HW, Brereton RE, Anderson RA, Wallace AM, Ho CK. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism. 2011;60(10):1475–81. doi:10.1016/j.metabol.2011.03.002.
79. Mishra S, Das AK, Das S. Hypovitaminosis D and associated cardiometabolic risk in women with PCOS. J Clin Diagn Res. 2016;10(5):BC01–4. doi:10.7860/JCDR/2016/19407.7771.
80. Jia XZ, Wang YM, Zhang N, Guo LN, Zhen XL, Li H, et al. Effect of vitamin D on clinical and biochemical parameters in polycystic ovary syndrome women: a meta-analysis. J Obstet Gynaecol Res. 2015;41(11):1791–802. doi:10.1111/jog.12793.
81. Tsakova AD, Gateva AT, Kamenov ZA. 25(OH) vitamin D levels in premenopausal women with polycystic ovary syndrome and/or obesity. Int J Vitam Nutr Res. 2012;82(6):399–404. doi:10.1024/0300-9831/a000137.
82. Velija-Asimi Z. Evaluation of the association of vitamin D deficiency with gonadotropins and sex hormone in obese and non-obese women with polycystic ovary syndrome. Med Glas (Zenica). 2014;11(1):170–6.
83. Muscogiuri G, Policola C, Prioletta A, Sorice G, Mezza T, Lassandro A, et al. Low levels of 25(OH)D and insulin-resistance: 2 unrelated features or a cause-effect in PCOS? Clin Nutr. 2012;31(4):476–80. doi:10.1016/j.clnu.2011.12.010.
84. Joham AE, Teede HJ, Cassar S, Stepto NK, Strauss BJ, Harrison CL, et al. Vitamin D in polycystic ovary syndrome: relationship to obesity and insulin resistance. Mol Nutr Food Res. 2016;60(1):110–8. doi:10.1002/mnfr.201500259.
85. Mahmoudi T, Gourabi H, Ashrafi M, Yazdi RS, Ezabadi Z. Calciotropic hormones, insulin resistance, and the polycystic ovary syndrome. Fertil Steril. 2010;93(4):1208–14. doi:10.1016/j.fertnstert.2008.11.031.
86. Hahn S, Haselhorst U, Tan S, Quadbeck B, Schmidt M, Roesler S et al. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association. 2006;114(10):577–83. doi:10.1055/s-2006-948308.
87. Yildizhan R, Kurdoglu M, Adali E, Kolusari A, Yildizhan B, Sahin HG, et al. Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch Gynecol Obstet. 2009;280(4):559–63. doi:10.1007/s00404-009-0958-7.
88. Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber TR, et al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol / European Federation of Endocrine Societies. 2009;161(4):575–82. doi:10.1530/EJE-09-0432.
89. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16(4):347–63. doi:10.1093/humupd/dmq001.
90. Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, et al. Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010;152(5):307–14. doi:10.7326/0003-4819-152-5-201003020-00009.
91. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab. 2004;89(5):2160–5. doi:10.1210/jc.2003-031096.
92. Sahin S, Eroglu M, Selcuk S, Turkgeldi L, Kozali S, Davutoglu S, et al. Intrinsic factors rather than vitamin D deficiency are related to insulin resistance in lean women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2014;18(19):2851–6.
93. Ganie MA, Marwaha RK, Nisar S, Farooqi KJ, Jan RA, Wani SA, et al. Impact of hypovitaminosis D on clinical, hormonal and insulin sensitivity parameters in normal body mass index polycystic ovary syndrome women. J Obstet Gynaecol. 2016;36(4):508–12. doi:10.3109/01443615.2015.1103715.
94. Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol. 2005;62(1):37–43. doi:10.1111/j.1365-2265.2004.02170.x.
95. Diamanti-Kandarakis E, Piperi C, Patsouris E, Korkolopoulou P, Panidis D, Pawelczyk L, et al. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol. 2007;127(6):581–9. doi:10.1007/s00418-006-0265-3.
96. Irani M, Minkoff H, Seifer DB, Merhi Z. Vitamin D increases serum levels of the soluble receptor for advanced glycation end products in women with PCOS. J Clin Endocrinol Metab. 2014;99(5):E886–90. doi:10.1210/jc.2013-4374.
97. Selimoglu H, Duran C, Kiyici S, Ersoy C, Guclu M, Ozkaya G, et al. The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. J Endocrinol Investig. 2010;33(4):234–8. doi:10.3275/6560.
98. Wehr E, Pieber TR, Obermayer-Pietsch B. Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women: a pilot study. J Endocrinol Investig. 2011;34(10):757–63. doi:10.3275/7748.
99. Ardabili HR, Gargari BP, Farzadi L. Vitamin D supplementation has no effect on insulin resistance assessment in women with polycystic ovary syndrome and vitamin D deficiency. Nutr Res. 2012;32(3):195–201. doi:10.1016/j.nutres.2012.02.001.
100. Raja-Khan N, Shah J, Stetter CM, Lott ME, Kunselman AR, Dodson WC, et al. High-dose vitamin D supplementation and measures of insulin sensitivity in polycystic ovary syndrome: a randomized, controlled pilot trial. Fertil Steril. 2014;101(6):1740–6. doi:10.1016/j.fertnstert.2014.02.021.
101. Bonakdaran S, Mazloom Khorasani Z, Davachi B, Mazloom KJ. The effects of calcitriol on improvement of insulin resistance, ovulation and comparison with metformin therapy in PCOS patients: a randomized placebo- controlled clinical trial. Iran J Reprod Med. 2012;10(5):465–72.
102. Dravecka I, Figurova J, Javorsky M, Petrikova J, Valkova M, Lazurova I. The effect of alfacalcidiol and metformin on phenotype manifestations in women with polycystic ovary syndrome - a preliminary study. Physiol Res. 2016;23;65(5):815–22.
103. Sourial S, Tempest N, Hapangama DK. Theories on the pathogenesis of endometriosis. Int J Reprod Med. 2014;2014:179515. doi:10.1155/2014/179515.
104. Miyashita M, Koga K, Izumi G, Sue F, Makabe T, Taguchi A, et al. Effects of 1,25-Dihydroxy vitamin D3 on endometriosis. J Clin Endocrinol Metab. 2016;101(6):2371–9. doi:10.1210/jc.2016-1515.
105. Mariani M, Vigano P, Gentilini D, Camisa B, Caporizzo E, Di Lucia P, et al. The selective vitamin D receptor agonist, elocalcitol, reduces endometriosis development in a mouse model by inhibiting peritoneal inflammation. Hum Reprod. 2012;27(7):2010–9. doi:10.1093/humrep/des150.
106. Abbas MA, Taha MO, Disi AM, Shomaf M. Regression of endometrial implants treated with vitamin D3 in a rat model of endometriosis. Eur J Pharmacol. 2013;715(1–3):72–5. doi:10.1016/j.ejphar.2013.06.016.
107. Yildirim B, Guler T, Akbulut M, Oztekin O, Sariiz G. 1-alpha,25-dihydroxyvitamin D3 regresses endometriotic implants in rats by inhibiting neovascularization and altering regulation of matrix metalloproteinase. Postgrad Med. 2014;126(1):104–10. doi:10.3810/pgm.2014.01.2730.
108. Vilarino FL, Bianco B, Lerner TG, Teles JS, Mafra FA, Christofolini DM, et al. Analysis of vitamin D receptor gene polymorphisms in women with and without endometriosis. Hum Immunol. 2011;72(4):359–63. doi:10.1016/j.humimm.2011.01.006.
109. Hartwell D, Rodbro P, Jensen SB, Thomsen K, Christiansen C. Vitamin D metabolites--relation to age, menopause and endometriosis. Scand J Clin Lab Invest. 1990;50(2):115–21.
110. Somigliana E, Panina-Bordignon P, Murone S, Di Lucia P, Vercellini P, Vigano P. Vitamin D reserve is higher in women with endometriosis. Hum Reprod. 2007;22(8):2273–8. doi:10.1093/humrep/dem142.
111. Ferrero S, Gillott DJ, Anserini P, Remorgida V, Price KM, Ragni N, et al. Vitamin D binding protein in endometriosis. J Soc Gynecol Investig. 2005;12(4):272–7. doi:10.1016/j.jsgi.2005.01.027.
112. Faserl K, Golderer G, Kremser L, Lindner H, Sarg B, Wildt L, et al. Polymorphism in vitamin D-binding protein as a genetic risk factor in the pathogenesis of endometriosis. J Clin Endocrinol Metab. 2011;96(1):E233–41. doi:10.1210/jc.2010-1532.
113. Hwang JH, Wang T, Lee KS, Joo JK, Lee HG. Vitamin D binding protein plays an important role in the progression of endometriosis. Int J Mol Med. 2013;32(6):1394–400. doi:10.3892/ijmm.2013.1506.
114. Borkowski J, Gmyrek GB, Madej JP, Nowacki W, Goluda M, Gabrys M et al. Serum and peritoneal evaluation of vitamin D-binding protein in women with endometriosis. Postepy Hig Med Dosw (Online). 2008;62:103–9.
115. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357(3):266–281. doi:10.1056/NEJMra070553.
116. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30. doi:10.1210/jc.2011-0385.